Zora at EAS 2016 Innsbruck


Zora participates 84th EAS Congress at Innsbruck, Austria.

Our CMO Reijo Laaksonen presents our latest results on cardiovascular risk prediction in statin treated patients at EAS 2016 on Tuesday 31st of May. The results show that plasma ceramides identify independently residual risk in statin treated coronary artery disease patients.